BLA 103786 · Ekr Therap
Retavase
Reteplase
NovelLast checked: Nov 20, 2026Latest source record: May 6, 1998 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1998
May 6, 1998
Approved uses
1
Original approval plus efficacy supplements
Registered trials
17
9 Phase 3, 2 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- RETAVASE · RETEPLASE 18.8MG/VIAL · VIAL, · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Reteplase" as an intervention, any sponsor and status, largest first.
- A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse)Pivotal-lookingCompleted
Centocor, Inc.Johnson & Johnson (Janssen) (JNJ)
NCT00046228 · 2,461 participants · Start Aug 2002 · Primary completion Jan 2008
Drug: abciximab placebo; reteplase placebo, abciximab, abciximab; Abciximab; reteplase; abciximab placebo; abciximab and 4 more · For: Myocardial Infarction
Sites: Phoenix, Arizona; Covina, California; Modesto, California · 227 sites in all
- Tenecteplase or Reteplase as Bridging Thrombolysis Before Thrombectomy in Acute Ischemic Cerebrovascular EventsPivotal-lookingRecruiting
Yongjun WangAcademic, hospital or other
NCT07748039 · 1,440 participants (planned) · Start Oct 16, 2026 · Primary completion Mar 1, 2029
Drug: rhTNK-tPA (0.25mg/kg); Reteplase 10 Units (U) plus a second dose of reteplase 10 U · For: Acute Ischemic Stroke; Large Vessel Occlusion; Anterior Circulation Brain Infarction
Sites: Beijing, China; Wuhan, China; Xiangtan, China · 5 sites in all
- A Study of r-PA Treating Patients With Acute Ischemic Stroke(RAISE)Pivotal-lookingCompleted
Angde Biotech Pharmaceutical Co., Ltd.Industry
NCT05295173 · 1,412 participants · Start Mar 21, 2022 · Primary completion Jun 22, 2023
Drug: Injection of recombinant human tissue plasminogen kinase derivatives; Recombinant human tissue plasminogen activator · For: Acute Ischemic Stroke
Sites: Bengbu, China; Beijing, China; Chongqing, China · 78 sites in all
- Efficacy and Safety of CUSA-081 in the Restoration of Central Venous Access Device (CVAD) FunctionalityPivotal-lookingTerminated
Chiesi Farmaceutici S.p.A.Industry
NCT03594175 · 462 participants · Start Feb 12, 2020 · Primary completion Jun 8, 2023
Drug: CUSA-081; Placebo and 1 more · For: Catheter Occlusion; Thrombosis
Sites: Little Rock, Arkansas; Redlands, California; Stockton, California · 77 sites in all
- Pre-hospital Administration of Thrombolytic Therapy With Urgent Culprit Artery RevascularizationPivotal-lookingCompleted
The University of Texas Health Science Center, HoustonAcademic, hospital or other
NCT00178620 · 390 participants · Start Sep 2003 · Primary completion Dec 2009
Drug: Reteplase 10 Units (U) plus a second dose of reteplase 10 U; Reteplase 10 U · For: Heart Disease; Myocardial Infarction; Acute Myocardial Infarction
Sites: Houston, Texas
- Intravenous Thrombolytic Therapy for Acute Ischemic Stroke Patients with Low NIHSS and Non-disabling DeficitsPivotal-lookingNot yet recruiting
Second Affiliated Hospital, Zhejiang University, School of MedicineAcademic, hospital or other
NCT06115070 · 390 participants (planned) · Start Mar 1, 2025 · Primary completion Dec 31, 2027
Drug: Intravenous thrombolysis (alteplase and other guideline-recommended thrombolytic agents) · For: Thrombosis; Acute Ischemic Stroke (AIS)
Sites: Hangzhou, China
- Intravenous Thrombosis and Patients with Prior Ischemic Stroke Within 3 MonthsPivotal-lookingNot yet recruiting
Second Affiliated Hospital, Zhejiang University, School of MedicineAcademic, hospital or other
NCT06841978 · 306 participants (planned) · Start Mar 1, 2025 · Primary completion Jun 30, 2027
Drug: Intravenous Thrombolysis · For: Stroke; Acute Ischemic Stroke
- Intravenous Thrombolysis and NOACPivotal-lookingRecruiting
Second Affiliated Hospital, Zhejiang University, School of MedicineAcademic, hospital or other
NCT06749834 · 280 participants (planned) · Start Jan 27, 2025 · Primary completion Dec 31, 2026
Drug: Intravenous thrombolysis · For: Acute Ischemic Stroke
Sites: Hangzhou, China; Taizhou, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Reteplase versus Alteplase for Acute Ischemic Stroke.
Li S, Gu HQ, Li H, et al. · N Engl J Med 2024 · Clinical Trial, Phase III, Comparative Study
- Patency trials with reteplase (r-PA): what do they tell us?
Bode C, Nordt TK, Peter K, et al. · Am J Cardiol 1996 · Clinical Trial, Comparative Study
- Reteplase versus alteplase for acute ischemic stroke: Meta-analysis.
Alkhiri A, Salamatullah HK, Alturki F, et al. · Am J Emerg Med 2025 · Meta-Analysis, Comparative Study
- [New thrombolytic agents in myocardial infarction].
Helft G, Elalamy I, Beygui F, et al. · Arch Mal Coeur Vaiss 1999 · Clinical Trial, Clinical Trial, Phase II
- Comparative efficacy and safety of tissue plasminogen activators (tPA) in acute ischemic stroke: A systematic review and network meta-analysis of randomized controlled trials.
Shahid S, Saeed H, Iqbal M, et al. · J Stroke Cerebrovasc Dis 2025 · Systematic Review, Network Meta-Analysis
- Evaluation of the time saved by prehospital initiation of reteplase for ST-elevation myocardial infarction: results of The Early Retavase-Thrombolysis in Myocardial Infarction (ER-TIMI) 19 trial.
Morrow DA, Antman EM, Sayah A, et al. · J Am Coll Cardiol 2002 · Clinical Trial, Multicenter Study
Sponsor: Ekr Therap
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.